Onconetix, Inc. (ONCO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Onconetix reported revenue of $815,371, down 67.7% from $2.5M the year before. Net income was -$14.0M (a -1721.0% net margin), or -$828.00 per diluted share. Gross margin was 77.6% and operating margin was -2190.0%. Operating activities generated -$9.7M of cash, leaving -$9.7M of free cash flow. At fiscal year end, Onconetix held $24.9M in total assets against $9.2M in total liabilities.
Open the full interactive Onconetix financials → Quarterly statements, key ratios, valuation history and price charts.
Onconetix Key Stats
| Share Price | $0.56 |
|---|---|
| Market Cap | $1.2M |
| Revenue YoY Growth | -67.7% |
| 52-Week Range | $0.56 – $189.50 |
| Shares Outstanding | 2.2 million (basic, 2026 Q2) |
Onconetix Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $58,465 | $2.5M | $815,371 |
| Cost of Goods Sold | — | — | $35,000 | $35,000 |
| Gross Profit | — | -$1.1M | $1.1M | $632,913 |
| Operating Income | -$13.5M | -$36.0M | -$56.5M | -$17.9M |
| Pre-Tax Income | $3.16T | -$37.4M | -$59.7M | -$14.0M |
| Income Tax | $3.16T | -$12,593 | -$1.0M | $525 |
| Net Income | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
| Diluted EPS | -$187000.00 | -$372300.00 | -$91162.50 | -$828.00 |
Onconetix Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $303,651 | $303,596 | $21,457 | $17,120 |
| Net Income | -$8.8M | $5.7M | -$4.2M | -$2.9M |
| Diluted EPS | -$312.50 | $6.05 | -$67.10 | -$1.28 |
Onconetix Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $25.8M | — | — | — |
| Current Assets | $26.3M | $5.8M | $950,267 | $6.1M |
| Total Assets | $26.3M | $87.5M | $28.2M | $24.9M |
| Current Liabilities | $3.9M | $17.2M | $18.3M | $9.1M |
| Total Long-Term Debt | — | $9.7M | — | — |
| Total Liabilities | $3.9M | $21.9M | $18.6M | $9.2M |
| Shareholders' Equity | $22.4M | -$5.6M | $8.5M | $15.8M |
Onconetix Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$8.7M | -$13.6M | -$10.5M | -$9.7M |
| Cash From Investing | -$9,339 | -$8.6M | -$28,471 | — |
| Cash From Financing | $32.5M | $1.0M | $6.7M | $14.5M |
| Free Cash Flow | -$8.7M | -$13.6M | -$10.5M | -$9.7M |
Figures from Onconetix's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Onconetix financials page for every line item.
Onconetix Company Profile
| Ticker | ONCO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cincinnati, Ohio |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001782107 |
Frequently Asked Questions
What was Onconetix's revenue in fiscal 2025?
Onconetix (ONCO) reported revenue of $815,371 for fiscal 2025.
What is Onconetix's annual revenue history?
Onconetix's annual revenue by fiscal year: 2022: $0; 2023: $58,465; 2024: $2.5M; 2025: $815,371.
What was Onconetix's net income in fiscal 2025?
Onconetix reported net income of -$14.0M for fiscal 2025.
What was Onconetix's earnings per share (EPS) in fiscal 2025?
Onconetix's diluted EPS was -$828.00 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Onconetix generate in fiscal 2025?
Onconetix generated -$9.7M of free cash flow in fiscal 2025.
What was Onconetix's revenue last quarter?
In its most recent reported quarter (2026 Q2), Onconetix reported revenue of $17,120.
How many shares of Onconetix are outstanding?
Onconetix reported a weighted average of 2.2 million basic shares outstanding in 2026 Q2.
What is Onconetix's market cap?
Based on its latest closing price, Onconetix (ONCO) has a market capitalization of about $1.2M.
When does Onconetix's fiscal year end?
Onconetix's fiscal year end, as registered with the SEC, is December 31.
Where is Onconetix headquartered?
Onconetix lists its business address in Cincinnati, Ohio in its SEC filings.